Open-Angle Glaucoma Clinical Trial Pipeline Analysis: 18+ Key Companies Shaping the Future of Open-Angle Glaucoma Therapeutics | DelveInsight

DelveInsight's Open-Angle Glaucoma Pipeline Insight 2026 report provides comprehensive global coverage of available and pipeline Open-Angle Glaucoma therapies across various stages of clinical and nonclinical development. More than 18 companies are working to advance 20+ pipeline drugs, with pharmaceutical and biotechnology companies developing novel therapeutic approaches to address the challenges associated with intraocular pressure control and progressive optic nerve damage.

Key takeaways from the Open-Angle Glaucoma Clinical Trial Landscape Report

• DelveInsight's Open-Angle Glaucoma pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Open-Angle Glaucoma treatment.
• Key Open-Angle Glaucoma companies such as Huons Co., Ltd., Qlaris Bio, Inc., ONL Therapeutics, iVIEW Therapeutics, Inc., Ocular Therapeutix, Inc., Nicox Ophthalmics, Inc., Bausch & Lomb Incorporated, Glaukos Corporation, and Omikron Italia S.r.l., among others, are involved in developing therapies for the indication.
• Promising Open-Angle Glaucoma pipeline therapies in various stages of development include HUC3-637, QLS-111, Xelafaslatide (ONL1204), IVW-2001 (GVB-2001), and others.
• The pipeline includes Phase III, Phase II, Phase I/II, preclinical, discovery, discontinued, and inactive candidates, reflecting a diverse therapeutic development landscape.

Request a sample and discover the recent advances in Open-Angle Glaucoma treatment drugs:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Open-Angle Glaucoma?

Open-angle glaucoma is a chronic, progressive, and irreversible optic neuropathy and represents the most common form of glaucoma. It is characterized by an anatomically open anterior chamber angle along with structural changes to the optic nerve head and retinal nerve fiber layer. In open-angle glaucoma, the drainage angle between the cornea and iris remains open, but impaired aqueous humor outflow can contribute to increased intraocular pressure and progressive optic nerve damage.
Open-angle glaucoma can be classified into primary and secondary forms. Primary open-angle glaucoma has no obvious underlying cause, with age-related changes in the trabecular meshwork contributing to increased resistance to fluid drainage. Secondary open-angle glaucoma occurs when another condition contributes to or accelerates dysfunction of the drainage system.
Symptoms may include gradual loss of peripheral vision, difficulty seeing objects at the edges of the visual field, missing letters while reading, and reduced visual contrast in low-light conditions. However, many individuals may not notice changes during the early stages, allowing the disease to progress silently and cause irreversible vision loss.
Treatment primarily aims to lower intraocular pressure and prevent further optic nerve damage. Management may include eye drops such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors. When medical treatment is insufficient or poorly tolerated, laser trabeculoplasty and surgical interventions, including trabeculectomy, glaucoma drainage devices, and minimally invasive glaucoma surgeries, may be used.

Emerging Open-Angle Glaucoma Drug Profiles

HUC3-637: Huons Co., Ltd.
HUC3-637 is an investigational ophthalmic drug developed by Huons Co., Ltd. for the treatment of primary open-angle glaucoma and ocular hypertension. It is a fixed-dose combination of dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker, formulated as a topical eye drop. The drug is designed to reduce intraocular pressure by decreasing aqueous humor production through dual mechanisms. HUC3-637 is currently being evaluated in Phase III development for Open-Angle Glaucoma.

QLS-111: Qlaris Bio, Inc.
QLS-111 is a novel formulation based on an ATP-sensitive potassium (KATP) channel modulator platform. The drug is designed to reduce intraocular pressure by relaxing blood vessels and vascular-like tissues located distal to the trabecular meshwork. This mechanism is intended to decrease distal outflow resistance and lower episcleral venous pressure, which contributes to overall intraocular pressure regulation. QLS-111 has demonstrated sustained IOP reduction as monotherapy and in combination with standard treatments such as latanoprost. It is currently being evaluated in Phase II/III development for Open-Angle Glaucoma.

Xelafaslatide (ONL1204): ONL Therapeutics
Xelafaslatide (ONL1204) is a first-in-class small peptide that inhibits the Fas receptor. By blocking activation of the Fas pathway and related immune signaling, the therapy is designed to inhibit downstream cell-death signaling and inflammatory responses associated with retinal cell damage. This approach may help preserve retinal ganglion cells and other critical retinal cells. Xelafaslatide is currently being evaluated in Phase II development for Open-Angle Glaucoma.

IVW-2001 (GVB-2001): iVIEW Therapeutics, Inc.
IVW-2001 (GVB-2001) is an investigational gene therapy candidate developed by iVIEW Therapeutics for primary open-angle glaucoma. The therapy utilizes an optimized self-complementary AAV vector delivered through a single intracameral injection directly to the trabecular meshwork, which is a key anatomical site involved in aqueous outflow resistance. By modulating cellular function and enhancing aqueous humor outflow, GVB-2001 is designed to provide rapid and durable intraocular pressure control. It is currently being evaluated in Phase I/II development for Open-Angle Glaucoma.

Learn more about the novel and emerging Open-Angle Glaucoma pipeline therapies:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Open-Angle Glaucoma Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery, Discontinued & Inactive
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Key Open-Angle Glaucoma Companies: Huons Co., Ltd., Qlaris Bio, Inc., ONL Therapeutics, iVIEW Therapeutics, Inc., Ocular Therapeutix, Inc., Nicox Ophthalmics, Inc., Bausch & Lomb Incorporated, Glaukos Corporation, Omikron Italia S.r.l., and others
• Key Open-Angle Glaucoma Pipeline Therapies: HUC3-637, QLS-111, Xelafaslatide (ONL1204), IVW-2001 (GVB-2001), OTX-TIC, AR-17043 Ophthalmic Solution, NCX 470, BL1107, GLK-311, WB007, and Citicoline.

Dive deep into rich insights for new drugs for Open-Angle Glaucoma treatment, visit:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Open-Angle Glaucoma Pipeline Report Introduction
2. Open-Angle Glaucoma Pipeline Report Executive Summary
3. Open-Angle Glaucoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Open-Angle Glaucoma Pipeline Therapeutics
6. Open-Angle Glaucoma Pipeline: Late Stage Products (Phase III)
7. Open-Angle Glaucoma Pipeline: Mid Stage Products (Phase II)
8. Open-Angle Glaucoma Pipeline: Early Stage Products (Phase I/II)
9. Open-Angle Glaucoma Pipeline: Preclinical and Discovery Stage Products
10. Open-Angle Glaucoma Pipeline Therapeutics Assessment
11. Inactive Products in the Open-Angle Glaucoma Pipeline
12. Open-Angle Glaucoma Pipeline Development Activities
13. Key Companies
14. Key Products in the Open-Angle Glaucoma Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Open-Angle Glaucoma pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.